Editas Medicine Receives Approval To Initiate Its Phase 1/2 Strive Clinical Trial Of EDIT-401 In Patients With Heterozygous Familial Hypercholesterolemia In Australia
TriSalus Life Sciences, Lakefront Biotherapeutics, Editas Medicine And Other Big Stocks Moving Higher On Wednesday